Abstract <p>¹⁷⁷Lu is one of the most widely used therapeutic radionuclides in nuclear medicine. The most promising procedure for its production is isolation from neutron-irradiated ytterbium targets enriched in ¹⁷⁶Yb. Today, ¹⁷⁷Lu is produced in the world at ten reactors, whereas the demand for this radionuclide steadily increases. In this study, a procedure was developed for producing ¹⁷⁷Lu at the IRT-T research reactor (Tomsk, Russia) using ion-exchange chromatography with the column heating and elution with an α-HIBA solution with gradient рН. Conditions were found for producing a no-carrier-added ¹⁷⁷Lu solution from ytterbium of natural isotope composition. The procedure was tested with an enriched ytterbium target. The ¹⁷⁷Lu solutions obtained meets the requirements of the Russian Federation Pharmacopoeia. The process developed will be used for producing ¹⁷⁷Lu at the IRT-T reactor for use in nuclear therapy.</p>